Caris Life Sciences raised full-year guidance as Q2 revenue surged 45% on a jump in molecular profiling services, including new Medicare reimbursement for its Caris ChromoSeq whole-genome plus whole-transcriptome assay in myeloid malignancies. The company also said it received its first Medicare reimbursement at the approved rate of $3,228. Caris tied further tailwinds to a new version of its MI Clarity cancer recurrence platform, expanding decision support to chemotherapy and extended endocrine therapy beyond the initial five-year frame. It also plans to move into minimal residual disease space with a planned launch of the Caris MRD assay, combining tumor-informed and tumor-naïve approaches. For the diagnostics and precision oncology ecosystem, the combination of reimbursement milestones and product expansion into MRD highlights an emphasis on turning profiling into actionable treatment decisions over time.